Ilaria Bacigalupo
Overview
Explore the profile of Ilaria Bacigalupo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
602
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Salemme S, Lombardo F, Lacorte E, Sciancalepore F, Remoli G, Bacigalupo I, et al.
Alzheimers Dement (Amst)
. 2025 Mar;
17(1):e70074.
PMID: 40078377
Introduction: Knowledge gaps remain about the prognosis of mild cognitive impairment (MCI). Conversion rates to dementia vary widely, and reversion to normal cognition has gained attention. This review updates evidence...
2.
Vaccaro R, Lorenzini P, Giaquinto F, Matascioli F, Carnevale G, Sciancalepore F, et al.
Aging Clin Exp Res
. 2024 Dec;
37(1):1.
PMID: 39704981
Background: The Italian Fund for Alzheimer's and other dementias approved in 2020 enabled the conducting of a survey in the Italian Centers for Cognitive Disorders and Dementias (CCDDs) to analyse...
3.
Sciancalepore F, Lombardi N, Valdiserra G, Bonaso M, Cappello E, Hyeraci G, et al.
Neuroepidemiology
. 2024 Oct;
:1-14.
PMID: 39380477
Introduction: No systematic reviews were published in the last years investigating epidemiological data, involving myasthenia gravis (MG) and related myasthenic syndromes. This systematic review aimed to estimate the prevalence, incidence,...
4.
Paoletti O, Hyeraci G, Finochietti M, Celani M, Bacigalupo I, Lombardi N, et al.
Eur J Neurol
. 2024 Sep;
31(12):e16470.
PMID: 39297678
Background And Purpose: The purpose was to describe the use patterns of pharmacological and non-pharmacological therapies and investigate potential determinants of riluzole use in patients newly diagnosed with amyotrophic lateral...
5.
Giaquinto F, Lorenzini P, Salvi E, Carnevale G, Vaccaro R, Matascioli F, et al.
J Alzheimers Dis
. 2024 Aug;
101(2):509-524.
PMID: 39213073
Background: The wait for the upcoming disease-modifying therapies (DMT) for Alzheimer's disease in Europe is raising questions about the preparedness of national healthcare systems to conduct accurate diagnoses and effective...
6.
Lombardo F, Lorenzini P, Mayer F, Massari M, Piscopo P, Bacigalupo I, et al.
Diagn Progn Res
. 2024 Jul;
8(1):11.
PMID: 39049042
Background: In recent years, significant efforts have been directed towards the research and development of disease-modifying therapies for dementia. These drugs focus on prodromal (mild cognitive impairment, MCI) and/or early...
7.
Bacigalupo I, Finocchietti M, Paoletti O, Bargagli A, Brunori P, Lombardi N, et al.
Epidemiol Prev
. 2024 Jul;
48(3):201-209.
PMID: 38995133
Objectives: to estimate Amyotrophic Lateral Sclerosis (ALS) incidence and prevalence in three Italian Regions (Lazio, Tuscany, and Umbria), using health administrative databases. Design: retrospective population-based study. Setting And Participants: ALS...
8.
Bacigalupo I, Giaquinto F, Salvi E, Carnevale G, Vaccaro R, Matascioli F, et al.
Neurol Sci
. 2023 Aug;
45(2):525-538.
PMID: 37592124
Introduction: A new national survey has been carried out by the Italian Centers for Cognitive Disorders and Dementias (CCDDs). The aim of this new national survey is to provide a...
9.
Cascini S, Canevelli M, Agabiti N, Angelici L, Davoli M, Bacigalupo I, et al.
J Alzheimers Dis
. 2023 Feb;
92(3):843-852.
PMID: 36806510
Background: A crucial step for planning effective public health policies for migrants with dementia is the collection of data on the local dimensions of the phenomenon and patients' characteristics. Objective:...
10.
Ancidoni A, Lacorte E, Bacigalupo I, Lombardo F, Vanacore N
Lancet Neurol
. 2023 Jan;
22(2):111.
PMID: 36681442
No abstract available.